Tender detail

Amiwantamab for the treatment of lung cancer and pleural mesothelioma (B.6)

Summary

The procurement concerns the 12-month supply of Amiwantamab for the treatment of lung cancer and pleural mesothelioma, in a subcutaneous dosage form. No variants, options or lots are provided for. Price is the only award criterion, weighted at 100%. Bids must be submitted electronically through the e-proPublico platform by 17 September 2026 at 11:00. The required declarations, product documentation and evidence of the necessary pharmaceutical trading authorisations must be submitted with the bid.

Reference number
2026/BZP 00415465/01
Buyer
Uniwersytecki Szpital Kliniczny w Poznaniu
Country
Poland (POL)
Procedure
Basic procedure
CPV
33600000 Pharmaceutical products
Deadline
2026-09-17
Status
Open
Contract subject
Supplies
Estimated value
Not published
Source
POL_BZP

More tender information after sign-in

The public view shows key tender details. Sign in to open official links, documents and AI tender support.